Ibiglustat

InvivoChem Cat #:V3367CAS #:1401090-53-6Purity >=98%

Description: Ibiglustat (formerly known as Venglustat; SAR402671; GZ402671; GZ-452; Genz-682452) is a novel, brain-penetrant, potent and selective allosteric Glucosylceramide synthase (GCS) inhibitor and ceramide glucosyltransferase inhibitor. It has the potential for treating PD Parkinson’s disease and SRT in Fabry’s and Gaucher’s. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.

Description:

References: J Inherit Metab Dis. 2014 Nov; 37(6):1013-22.; Future Med. Chem. (2017) 9(14), 1687–1700.

References:

-20C for 3 years in powder form

Synonym: Venglustat; SAR402671; SAR-402671; SAR 402671; GZ-402671; GZ402671; GZ402671; Genz-682452-AA; Ibiglustat; GZ-452; Genz-682452
Chemical Name: (3S)-1-azabicyclo[2.2.2]octan-3-yl N-{2-[2-(4-fluorophenyl)- 1, 3-thiazol-4-yl]propan-2-yl}carbamate
InChi Key: YFHRCLAKZBDRHN-MRXNPFEDSA-N
InChi Code: InChI=1S/C20H24FN3O2S/c1-20(2, 17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6, 12-13, 16H, 7-11H2, 1-2H3, (H, 23, 25)/t16-/m1/s1
SMILES Code: O=C(O[CH]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C